PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pfizer PFE is one of the leading oncology drugmakers with a strong presence across breast, genitourinary, thoracic, gastrointestinal and blood cancers. The company has a well-established portfolio of approved cancer therapies and a robust pipeline, focusing on diverse modalities such as small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. Pfizer's revenues from the oncology portfolio grew 8% year over year in 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Oncology sales comprised around 27% of the company's total revenues in 2025. Besides working on expanding the labels of approved cancer drugs, Pfizer is also focusing on advancing its oncology pipeline with several candidates in mid-to-late-stage development. Key oncology candidates in late-stage development include atirmociclib (a CDK4 inhibitor for metastatic breast cancer) and sigvotatug vedotin (an ADC for metastatic non-small cell lung cancer or NSCLC).
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer aims for wider use of PARP drug in prostate cancer with new data [Yahoo! Finance]Yahoo! Finance
- The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients [Fortune]Fortune
- TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate CancerBusiness Wire
- Contraceptives Drugs Market Size to Reach USD 46.24 Billion by 2035; Rising Awareness of Family Planning Driving Market Growth – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Pfizer: I'm Still Expecting A Massive Rebound [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/16/26 - Form 4
- 3/12/26 - Form ARS
- 3/12/26 - Form DEFA14A
- PFE's page on the SEC website